How to Turn a Scientific Paper Into a Compelling Pitch Deck in 48 Hours

Deep tech founders face a paradox that software startup founders never encounter: the very complexity that makes their technology defensible is the same complexity that makes it nearly impossible to pitch. Most deep tech founders default to one of two broken templates — either they build an academic presentation, which is dense, jargon-heavy, and structured like a conference paper, or they grab a generic startup deck template that strips out all the science and leaves investors unable to evaluate the core claim.

The correct pitch deck for a researcher-founder is neither of these. It is a document that does one specific job in a specific sequence: it earns the investor's attention with a problem they care about, establishes the credibility of the science that addresses it, makes the commercial opportunity legible, and closes with a specific ask. It takes everything in the paper and reorganises it around the investor's decision-making process rather than the journal's peer review criteria.

This guide shows you how to do that reorganisation in 48 hours — using the paper you have already written as the source material, and a 15-slide template as the structure.

Before You Open a Single Slide: The Translation Step

The 48-hour process begins not with PowerPoint but with a translation exercise. Take a blank document and answer five questions in plain language — no jargon, no citations, no methodology. Every slide in the deck that follows draws its content from one of these five answers. If you cannot answer all five before opening the deck template, the 48-hour process will not produce a fundable pitch — it will produce a reorganised paper.

The Template: 15 Slides

Aim for 15-20 slides — enough to cover the essential deep tech elements without overwhelming the reader. What follows is a 15-slide template with, for each slide, the specific question it answers, the content it should contain, and the most common mistake researchers make when filling it in.

1. The Hook

   Answers Why should the investor keep reading?

   Content One sentence naming the problem and its scale. One sentence naming what you found. Nothing else. Example: "Sepsis kills 11 million people annually. We have developed a diagnostic that identifies it 6 hours earlier than any existing method — from a single blood draw."

   Mistake Beginning with the laboratory name, university affiliation, or paper title. The investor does not yet know why they should care about any of those things. Earn their attention first.

2. The Problem

   Answers How bad is this problem, and who is affected?

   Content Three elements: the population affected (who and how many), the current inadequate solution (what exists and why it fails), and the cost of failure (financial, clinical, environmental, or human). One striking statistic per element. Source every number.

   Mistake Framing the problem in academic terms ("a significant gap exists in the literature regarding...") rather than human or commercial terms.

3. The Market Opportunity

   Answers How large is the commercial prize?

   Content TAM, SAM, and SOM — each with a dollar figure and brief justification. Use bottom-up market sizing: start from the number of patients, procedures, or facilities, multiply by a realistic price. The progression from TAM to SOM shows you understand the difference between the universe of the problem and the realistic near-term market.

   Mistake Citing a market report number ("the global diagnostics market is $85 billion") without connecting it to the specific segment your technology addresses. Investors spot top-down sizing immediately.

4. Why Now

   Answers Why is this the right moment to commercialise this technology?

   Content Two or three specific, externally verifiable changes in the environment that make this technology timely: regulatory shifts, clinical guideline updates, cost changes in adjacent technologies, changes in reimbursement, or emerging data mandates.

   Mistake Skipping this slide, or filling it with generic statements about "growing market demand." The best answers to "why now" are specific and verifiable.

5. The Technology

   Answers What did you actually discover or develop?

   Content A simplified explanation in three sentences accessible to a non-specialist, followed by one figure from the paper — the clearest visual evidence of the result. Label axes in plain language. Remove statistical notation a non-specialist cannot parse on a slide.

   Mistake Over-engineering this slide. 60% of the technology explanation belongs in the appendix. The slide needs to communicate one thing: the result is real and better than the alternative by a meaningful, measurable margin.

6. The Evidence

   Answers How do we know this works?

   Content The key proof points from the paper in the most direct possible form. For a diagnostic: sensitivity, specificity, and comparison to current standard. For a material: the performance metric that matters to the end user vs. the commercial benchmark. For a drug candidate: the efficacy signal and the safety profile from the best available data.

   Mistake Including every result from the paper. Investors need the two or three numbers that prove the core claim. The full data set belongs in the data room.

7. Competitive Landscape

   Answers What else exists, and why is this better?

   Content A positioning map — not a 3x3 table with checkmarks — that plots the two most important competitive dimensions (performance vs. cost, efficacy vs. safety, speed vs. accuracy) and places your technology and the key competitors honestly within it.

   Mistake Claiming no competitors exist. There are always competitors — direct, indirect, and the status quo. A map that omits the strongest competitor destroys credibility faster than almost anything else.

8. IP and Defensibility

   Answers Why can't a larger player simply copy this?

   Content The IP position (patents filed or granted, with application numbers), the freedom-to-operate status, and additional sources of defensibility beyond the patent: proprietary data, manufacturing know-how, regulatory exclusivity, network effects, or switching costs.

   Mistake Presenting the patent application as if filing equals protection. Investors know the difference between a provisional and a granted patent, and between a patent covering the core mechanism and one covering a peripheral feature.

9. Regulatory Pathway

   Answers What has to happen before this can be sold, and how long will it take?

   Content The specific regulatory pathway in the relevant jurisdiction (CE mark, FDA 510(k), PMA, EMA marketing authorisation), the current TRL, the key milestones marking progress toward approval, and a realistic timeline. For each milestone: what it requires, what it costs, and what it proves to the next investor.

   Mistake "We will seek FDA approval" is not a regulatory strategy. "We are pursuing a 510(k) pathway based on predicate device X, with pre-submission meeting scheduled for Q3 2026" is.

10. Business Model

    Answers How does money flow from the market to the company?

    Content The revenue model (licensing, product sales, subscription, service), the pricing rationale (what the customer currently pays for the inadequate solution, and what premium a significantly better solution justifies), and the unit economics at scale.

    Mistake Treating this slide as aspirational. Investors are not looking for big numbers — they are looking for a demonstrated understanding of how the business works. A realistic model with conservative assumptions is more fundable than an aggressive model with no justification.

11. Go-to-Market

    Answers How does the technology reach its first customers?

    Content The specific first customer segment (not "hospitals" but "academic medical centres in Germany with existing biomarker testing infrastructure"), the entry pathway, and the early traction that already exists: a letter of intent, a pilot agreement, a named clinical partner, or a named industry partner.

    Mistake A go-to-market slide that describes the eventual commercial strategy rather than the path to the first paying customer. Investors want to know how the first revenue happens.

12. The Team

    Answers Why are these the people who can do this?

    Content The four or five people most relevant to the investor's assessment of execution risk. For each: one sentence of relevant background that directly connects their experience to a specific challenge the company faces.

    Mistake Listing academic credentials without connecting them to commercial execution. A professor with 25 years of laboratory experience has demonstrated scientific credibility; the investor also needs to know who will build the commercial infrastructure and manage the regulatory submission.

13. Milestones and Use of Funds

    Answers What will this money buy, and what will be true at the end of it?

    Content A 12-to-18-month milestone roadmap showing four or five specific, verifiable outcomes. For each: the specific target (quantified), the cost (approximate), and why reaching it de-risks the investment for the next round.

    Mistake Milestones that are activities rather than outcomes. "Conduct clinical trials" is an activity. "Complete 50-patient Phase I demonstrating safety profile consistent with regulatory submission" is an outcome. Investors fund outcomes.

14. The Ask

    Answers What specifically is being requested?

    Content The funding amount, the instrument (equity round, convertible note, grant-matched investment), the current valuation or valuation cap if relevant, and the closing timeline. One slide, no embellishment.

    Mistake Being vague about the ask to avoid anchoring the valuation discussion. Investors prefer specificity — it signals that the team has done the financial work and understands what they need and why.

15. The Closing Statement

    Answers What is the single most important thing to remember?

    Content Return to the hook from Slide 1, stated slightly differently, followed by the one number or fact that most powerfully demonstrates why the investment opportunity is compelling. Then stop.

    Mistake Ending with "thank you" and a list of contact details. The last thing the investor reads should be the argument, not the pleasantries.

The Appendix: Where the Paper Lives

Everything from the paper that did not fit in the 15 slides goes in the appendix: the full methodology, the complete results, the statistical analysis, the extended competitive landscape, the full regulatory assessment, the detailed financial model, the full IP claim scope.

The 48-Hour Schedule

1. Translation exercise only

   Answer the five questions. Do not open PowerPoint until all five answers exist in plain language. This is not the most interesting step. It is the most important one.

2. Problem, market, technology core

   Fill in Slides 1, 2, 3, and 5 — the problem, market, and technology core. These draw most directly from the paper. Write content in text boxes only; no design at this stage.

3. Evidence, competitive landscape, IP, regulatory

   Fill in Slides 4, 6, 7, 8, and 9. These require research beyond the paper itself. The competitive landscape research is the most time-consuming component and should not be skipped or approximated.

4. Business model, go-to-market, team, milestones, ask

   Fill in Slides 10, 11, 12, 13, and 14. These draw on knowledge the researcher has but has often not assembled in investor-facing form.

5. Build the appendix

   Place everything from the paper that was not used in the 15 slides into clearly labelled appendix sections. Label each section with the question it answers during due diligence.

6. Design pass

   Apply a consistent visual template. Ensure every slide has one clear headline in plain language. Remove all jargon that has not been defined. Replace every y-axis label that requires domain knowledge with plain-language equivalents.

7. Review pass — as the investor

   Read the deck aloud from start to finish as if you are the investor, not the researcher. Mark every sentence where you noticed yourself needing prior knowledge to understand the claim. Have one person who is not in your field read it and mark every sentence where they lost the thread. Replace or define each one.

At the end of 48 hours, you will have a document that could not have been produced by recombining the paper's existing sections — because it is organised around a completely different set of questions. It takes the same evidence and makes it legible to the people who can act on it. That is the entire purpose.